Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241105 | 0.90 | DPP4 (0.78) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Hydrochloric Acid SCHEMBL1241140 | 0.89 | DPP4 (0.62) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1243477 | 0.86 | DPP4 (0.77) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL5463563 | 0.80 | DPP4 (0.57) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1243467 | 0.78 | DPP4 (1.00) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1242729 | 0.78 | DPP4 (0.73) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1241094 | 0.78 | DPP4 (0.75) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1241087 | 0.78 | DPP4 (0.75) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1241130 | 0.78 | DPP4 (1.00) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL1241137 | 0.78 | DPP4 (0.75) | DPP4CHRM1CHRM2CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778690-B1 | Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-08-22 | — | — | EP | disclosed |
| US-7879864-B2 | dipeptidyl peptidase IV inhibitors such as 8-(2-Amino-2-methylpropoxy)-3-methyl-7-(3-methylbut-2-enyl)-1-(2-oxo-2-phenylethyl)-3,7-dihydropurine-2,6-dione, used for the treatment of elevated blood glucose levels and metabolic disorders; antidiabetic agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20070299090-A1 | SUBSTITUTED 8-AMINOALKOXY-XANTHINE COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299090-A1 | SUBSTITUTED 8-AMINOALKOXY-XANTHINE COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | DPP8, DPP4, DPP7 | DPP4 2/4885CHRM1 3312/4885CHRM2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.